Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103.2 USD | -0.58% | -4.60% | +2.39% |
Apr. 25 | US FDA sends warning to Cardinal Health for marketing unapproved devices | RE |
Apr. 24 | Evercore ISI Adjusts Cardinal Health's Price Target to $110 From $118, Keeps In Line Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company shows low valuation levels, with an enterprise value at 0.11 times its sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.39% | 25.1B | C+ | ||
+17.35% | 71.39B | C+ | ||
+5.38% | 8.59B | C | ||
+6.69% | 8.19B | B | ||
-20.96% | 7.91B | B- | ||
+0.49% | 4.54B | B- | ||
+17.12% | 4.31B | B+ | ||
-3.38% | 3.93B | B- | ||
-2.61% | 3.86B | B | ||
+22.08% | 3.64B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CAH Stock
- Ratings Cardinal Health, Inc.